RxDoctor Payments Data

John Patterson, MD

Family Medicine · El Paso, TXNPI 1568653269

Payments from drug & device makers

$10,139in general payments, 2019–2025

Across 525 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Abbott$1K
  • Lilly USA, LLC$932
  • Boehringer Ingelheim$735
  • AbbVie$595
  • Amgen$544
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$10,093100%
  • Education$160%
  • Other$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,139 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$79,388
Medicare patients
140
Services billed
972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide184$340,934
JardianceEmpagliflozin130$201,180
RybelsusSemaglutide66$158,915
ProliaDenosumab81$141,879
EliquisApixaban105$135,766
MounjaroTirzepatide88$125,971
TrulicityDulaglutide60$88,927
JanuviaSitagliptin Phosphate60$79,066
Tresiba Flextouch U-100Insulin Degludec53$69,217
FarxigaDapagliflozin Propanediol60$66,815
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog53$52,763
LinzessLinaclotide49$52,080
VascepaIcosapent Ethyl49$44,420
XareltoRivaroxaban26$33,776
MyrbetriqMirabegron30$33,541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,335$499,849250 claims
Lilly USA, LLCMounjaro, Trulicity$932$214,899148 claims
Boehringer IngelheimJardiance$735$201,180130 claims
AmgenProlia$544$141,87981 claims
PfizerEliquis$54$135,766105 claims
AstraZenecaFarxiga, Brilinta$218$85,58077 claims
MerckJanuvia$304$79,06660 claims
AbbVieLinzess$595$52,08049 claims
Johnson & JohnsonXarelto$406$33,77626 claims
Astellas Pharma US IncMyrbetriq$62$33,54130 claims
GSKTrelegy Ellipta$229$31,00636 claims
NovartisEntresto$99$20,97013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →